← All sources View original paper →
N=1 Reports on rapamycin.news
N=1 data from 3 participant(s). Tomnook (age 69M): −15% HRV / +2–3 bpm; Texasgirl: −6–8 ms HRV / +7–8 bpm RHR per cycle; Newbalance: Cyclical HRV suppression correlated with carb load; independ
N=1 Self-Experiment Data
Tomnook (age 69M)
- Protocol: Rapamycin 1mg escalating to 6mg over 5 weeks + indoor rowing 20 min/day
- Before: HRV 20–40 ms; occasional spikes >100 ms
- After: HRV −15% overall; RHR +2–3 bpm; BP 115/73 → 120/75
- Change: −15% HRV / +2–3 bpm
- Duration: 5 wks
- Device: Apple Watch + Oura + 24h BP + CGM
Texasgirl
- Protocol: Rapamycin 2mg + GFJ weekly (or 4mg + GFJ biweekly). Uses wearable to time next dose
- Before: Baseline: RHR high 50s / HRV 20 ms
- After: Post-dose: RHR mid 60s / HRV 12–14 ms; returns to baseline within days
- Change: −6–8 ms HRV / +7–8 bpm RHR per cycle
- Duration: Ongoing; dozens of cycles
- Device: Oura Ring
Newbalance
- Protocol: High-glycemic foods at night consistently tracked — compared before/after starting rapamycin to rule it out as variable
- Before: Baseline (normal evenings)
- After: Lower overnight HRV on high-glycemic evenings
- Change: Cyclical HRV suppression correlated with carb load; independent of rapamycin
- Duration: Ongoing observation
- Device: Oura Ring + HRV4Training
Outcomes
- Heart Rate Variability20ms (RMSSD)
- Resting Heart Rate3bpm (Beats Per Minute)
- Heart Rate Variability15ms (RMSSD)
- Heart Rate Variability12ms (RMSSD)
- Heart Rate Variability7ms (RMSSD)
- Resting Heart Rate8bpm (Beats Per Minute)